Vitiligo vulgaris
Conditions
Interventions
Transplantation of processed (autologous-cultured epithelium sheet) cells
Sponsors
Nishikawa Ayaka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients who are over 20 years old and obtain consent in writing. (2) Patients with a diagnosis of vitiligo vulgaris who have little or no effect on at least a few standard treatments (3) Patients with stable vitiligo that has not progressed within the past year and does not show obvious Koebner phenomenon
Exclusion criteria
Exclusion criteria: (1) Patients being treated for autoimmune diseases (2) Patients who are systemically administered steroids (corticosteroids) (3) Patients with skin malignancy, patients with suspected skin malignancy, or patients with a history of skin malignancy less than 5 years (4) Pregnant women, lactating women, patients who may be pregnant, patients who wish to become pregnant during the study period (5) Patients with severe heart disease (6) Patients with severe liver disease (7) End stage renal failure (8) Patients with severe blood coagulation disorder (9) Person with active infection (10) Persons with mental illness (11) HCV antibody, HBs antigen, HTLV-1 virus antibody or HIV antibody positive (12) Patients with allergic symptoms in cattle and mice (13)Patients with vitiligo area that cannot be covered with Specific Cell Products to be transplanted (14)Other patients who are determined to be inappropriate for participation in this study by the person in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of occurrences of serious adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate below contents, Successive observation of transplantation site Healing satisfaction survey Pain Transplant site infection | — |
Countries
Japan
Contacts
Public ContactDaisuke Mimura
Shonan Beauty Clinic, Shinjuku
Outcome results
None listed